Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Gastrointestinal Endoscopy

Volumn 85, Issue 1, 2017, Pages 2-21.e3

  Robertson, Douglas J ^a,b   Lee, Jeffrey K ^c   Boland, C Richard ^d   Dominitz, Jason A ^e   Giardiello, Francis M ^f   Johnson, David A ^g   Kaltenbach, Tonya ^h   Lieberman, David ⁱ   Levin, Theodore R ^j   Rex, Douglas K ^k  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j KAISER PERMANENTE MEDICAL CENTER   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ARTICLE; COCHRANE LIBRARY; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL TUMOR; COMPARATIVE EFFECTIVENESS; DIGITAL RECTAL EXAMINATION; FECES ANALYSIS; HUMAN; IMMUNOCHEMISTRY; MEDLINE; OCCULT BLOOD TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TUMOR DIAGNOSIS; COLORECTAL NEOPLASMS; CONSENSUS; EARLY CANCER DIAGNOSIS; OCCULT BLOOD; STANDARDS;

COLONOSCOPY; COLORECTAL NEOPLASMS; CONSENSUS; EARLY DETECTION OF CANCER; HEMOGLOBINS; HUMANS; IMMUNOCHEMISTRY; OCCULT BLOOD;

EID: 85003977135     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2016.09.025     Document Type: Article

References (120)

1. 1 American Cancer Society. Cancer of the colon and rectum. CA Cancer J Clin 30 (1980), 208–215.
2. 2 Hardcastle, J.D., Chamberlain, J.O., Robinson, M.H., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (1996), 1472–1477.
3. 3 Mandel, J.S., Bond, J.H., Church, T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328 (1993), 1365–1371.
4. 4 Kronborg, O., Fenger, C., Olsen, J., et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348 (1996), 1467–1471.
5. 5 Shaukat, A., Mongin, S.J., Geisser, M.S., et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 369 (2013), 1106–1114.
6. 6 Mandel, J.S., Church, T.R., Bond, J.H., et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343 (2000), 1603–1607.
7. 7 Jaffe, R.M., Kasten, B., Young, D.S., et al. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med 83 (1975), 824–826.
8. 8 Songster, C.L., Barrows, G.H., Jarrett, D.D., Immunochemical detection of fecal occult blood–the fecal smear punch-disc test: a new non-invasive screening test for colorectal cancer. Cancer 45 (1980), 1099–1102.
9. 9 Barrows, G.H., Burton, R.M., Jarrett, D.D., et al. Immunochemical detection of human blood in feces. Am J Clin Pathol 69 (1978), 342–346.
10. 10 Zorzi, M., Fedeli, U., Schievano, E., et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut 64 (2015), 784–790.
11. 11 Chiang, T.H., Chuang, S.L., Chen, S.L., et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology 147 (2014), 1317–1326.
12. 12 Chiu, H.M., Chen, S.L., Yen, A.M., et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer 121 (2015), 3221–3229.
13. 13 Centers for Disease Control and Prevention. Vital signs: colorectal cancer screening test use–United States, 2012. MMWR Morb Mortal Wkly Rep 62 (2013), 881–888.
14. 14 Guyatt, G.H., Oxman, A.D., Vist, G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008), 924–926.
15. 15 Whitlock, E.P., Lin, J.S., Liles, E., et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 149 (2008), 638–658.
16. 16 Lee, J.K., Liles, E.G., Bent, S., et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med, 160, 2014, 171.
17. 17 Fraser, C.G., Allison, J.E., Halloran, S.P., et al. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 104 (2012), 810–814.
18. 18 Kahi, C.J., Boland, C.R., Dominitz, J.A., et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 150 (2016), 758–768.e11.
19. 19 Allison, J.E., Sakoda, L.C., Levin, T.R., et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 99 (2007), 1462–1470.
20. 20 Allison, J.E., Tekawa, I.S., Ransom, L.J., et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 334 (1996), 155–159.
21. 21 Brenner, H., Tao, S., Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer 49 (2013), 3049–3054.
22. 22 Cheng, T.I., Wong, J.M., Hong, C.F., et al. Colorectal cancer screening in asymptomaic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. J Formos Med Assoc 101 (2002), 685–690.
23. 23 Chiang, T.H., Lee, Y.C., Tu, C.H., et al. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ 183 (2011), 1474–1481.
24. 24 Chiu, H.M., Lee, Y.C., Tu, C.H., et al. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol 11 (2013), 832–838 e1-2.
25. 25 de Wijkerslooth, T.R., Stoop, E.M., Bossuyt, P.M., et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol 107 (2012), 1570–1578.
26. 26 Itoh, M., Takahashi, K., Nishida, H., et al. Estimation of the optimal cut off point in a new immunological faecal occult blood test in a corporate colorectal cancer screening programme. J Med Screen 3 (1996), 66–71.
27. 27 Launoy, G.D., Bertrand, H.J., Berchi, C., et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 115 (2005), 493–496.
28. 28 Levi, Z., Birkenfeld, S., Vilkin, A., et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer 128 (2011), 2415–2424.
29. 29 Levi, Z., Rozen, P., Hazazi, R., et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 146 (2007), 244–255.
30. 30 Morikawa, T., Kato, J., Yamaji, Y., et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129 (2005), 422–428.
31. 31 Nakama, H., Kamijo, N., Abdul Fattah, A.S., et al. Validity of immunological faecal occult blood screening for colorectal cancer: a follow up study. J Med Screen 3 (1996), 63–65.
32. 32 Nakama, H., Yamamoto, M., Kamijo, N., et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 46 (1999), 228–231.
33. 33 Park, D.I., Ryu, S., Kim, Y.H., et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 105 (2010), 2017–2025.
34. 34 Nakazato, M., Yamano, H.-O., Matsushita, H.-O., et al. Immunologic fecal occult blood test for colorectal cancer screening. Jpn Med Assoc J, 49, 2006, 203.
35. 35 Parra-Blanco, A., Gimeno-Garcia, A.Z., Quintero, E., et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 45 (2010), 703–712.
36. 36 Sohn, D.K., Jeong, S.Y., Choi, H.S., et al. Single immunochemical fecal occult blood test for detection of colorectal neoplasia. Cancer Res Treat 37 (2005), 20–23.
37. 37 Imperiale, T.F., Ransohoff, D.F., Itzkowitz, S.H., et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370 (2014), 1287–1297.
38. 38 Hernandez, V., Cubiella, J., Gonzalez-Mao, M.C., et al. Fecal immunochemical test accuracy in average-risk colorectal cancer screening. World J Gastroenterol 20 (2014), 1038–1047.
39. 39 Zubero, M.B., Arana-Arri, E., Pijoan, J.I., et al. Population-based colorectal cancer screening: comparison of two fecal occult blood test. Front Pharmacol, 4, 2014, 175.
40. 40 Graser, A., Stieber, P., Nagel, D., et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 58 (2009), 241–248.
41. 41 Haug, U., Hundt, S., Brenner, H., Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 105 (2010), 682–690.
42. 42 Hundt, S., Haug, U., Brenner, H., Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 150 (2009), 162–169.
43. 43 Imperiale, T.F., Wagner, D.R., Lin, C.Y., et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 343 (2000), 169–174.
44. 44 Lieberman, D.A., Weiss, D.G., Bond, J.H., et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 343 (2000), 162–168.
45. 45 Crotta, S., Segnan, N., Paganin, S., et al. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 10 (2012), 633–638.
46. 46 Denters, M.J., Deutekom, M., Bossuyt, P.M., et al. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology 142 (2012), 497–504.
47. 47 Kapidzic, A., Grobbee, E.J., Hol, L., et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol 109 (2014), 1257–1264.
48. 48 McNamara, D., Leen, R., Seng-Lee, C., et al. Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght-Trinity College colorectal cancer screening programme with the faecal immunological test. Eur J Gastroenterol Hepatol 26 (2014), 1415–1421.
49. 49 Parente, F., Boemo, C., Ardizzoia, A., et al. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. Endoscopy 45 (2013), 27–34.
50. 50 Stegeman, I., van Doorn, S.C., Mundt, M.W., et al. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening. Cancer Epidemiol 39 (2015), 388–393.
51. 51 van Roon, A.H., Goede, S.L., van Ballegooijen, M., et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 62 (2013), 409–415.
52. 52 Jensen, C.D., Corley, D.A., Quinn, V.P., et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med 164 (2016), 456–463.
53. 53 Federici, A., Giorgi Rossi, P., Borgia, P., et al. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen 12 (2005), 83–88.
54. 54 Smith, A., Young, G.P., Cole, S.R., et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 107 (2006), 2152–2159.
55. 55 van Rossum, L.G., van Rijn, A.F., Laheij, R.J., et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135 (2008), 82–90.
56. 56 Hol, L., van Leerdam, M.E., van Ballegooijen, M., et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59 (2010), 62–68.
57. 57 Wong, C.K., Fedorak, R.N., Prosser, C.I., et al. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis 27 (2012), 1657–1664.
58. 58 Chubak, J., Bogart, A., Fuller, S., et al. Uptake and positive predictive value of fecal occult blood tests: a randomized controlled trial. Prev Med 57 (2013), 671–678.
59. 59 Hassan, C., Giorgi Rossi, P., Camilloni, L., et al. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 36 (2012), 929–940.
60. 60 Raginel, T., Puvinel, J., Ferrand, O., et al. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Gastroenterology 144 (2013), 918–925.
61. 61 Hol, L., Wilschut, J.A., van Ballegooijen, M., et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 100 (2009), 1103–1110.
62. 62 Vart, G., Banzi, R., Minozzi, S., Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med 55 (2012), 87–92.
63. 63 Tinmouth, J., Lansdorp-Vogelaar, I., Allison, J.E., Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut 64 (2015), 1327–1337.
64. 64 Robertson, D.J., Imperiale, T.F., Stool testing for colorectal cancer screening. Gastroenterology 149 (2015), 1286–1293.
65. 65 Segnan, N., Senore, C., Andreoni, B., et al. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst 97 (2005), 347–357.
66. 66 Segnan, N., Senore, C., Andreoni, B., et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology 132 (2007), 2304–2312.
67. 67 Khalid-de Bakker, C.A., Jonkers, D.M., Sanduleanu, S., et al. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res (Phila) 4 (2011), 1563–1571.
68. 68 Castells, A., Quintero, E., Alvarez, C., et al. Rate of detection of advanced neoplasms in proximal colon by simulated sigmoidoscopy vs fecal immunochemical tests. Clin Gastroenterol Hepatol 12 (2014), 1708–1716.e4.
69. 69 Quintero, E., Castells, A., Bujanda, L., et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 366 (2012), 697–706.
70. 70 CONFRIM trial. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01239082. Accessed: November 16, 2014.
71. 71 Screesco trial. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02078804. Accessed: November 16, 2014.
72. 72 Gupta, S., Halm, E.A., Rockey, D.C., et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Intern Med 173 (2013), 1725–1732.
73. 73 Hol, L., Kuipers, E.J., van Ballegooijen, M., et al. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer 130 (2012), 2096–2102.
74. 74 Senore, C., Ederle, A., Benazzato, L., et al. Offering people a choice for colorectal cancer screening. Gut 62 (2013), 735–740.
75. 75 van Roon, A.H., Wilschut, J.A., Hol, L., et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 9 (2011), 333–339.
76. 76 Wong, M.C., Ching, J.Y., Chan, V.C., et al. Diagnostic accuracy of a qualitative fecal immunochemical test varies with location of neoplasia but not number of specimens. Clin Gastroenterol Hepatol 13 (2015), 1472–1479.
77. 77 Guittet, L., Bouvier, V., Guillaume, E., et al. Colorectal cancer screening: why immunochemical faecal occult blood test performs as well with either one or two samples. Dig Liver Dis 44 (2012), 694–699.
78. 78 Goede, S.L., van Roon, A.H., Reijerink, J.C., et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 62 (2013), 727–734.
79. 79 Zauber, A.G., Lansdorp-Vogelaar, I., Knudsen, A.B., et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 149 (2008), 659–669.
80. 80 Day, L.W., Bhuket, T., Allison, J., FIT testing: an overview. Curr Gastroenterol Rep, 15, 2013, 357.
81. 81 Park, M.J., Choi, K.S., Lee, Y.K., et al. A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program. Scand J Gastroenterol 47 (2012), 461–466.
82. 82 Huang, Y., Li, Q., Ge, W., et al. Predictive power of quantitative and qualitative fecal immunochemical tests for hemoglobin in population screening for colorectal neoplasm. Eur J Cancer Prev 23 (2014), 27–34.
83. 83 Tannous, B., Lee-Lewandrowski, E., Sharples, C., et al. Comparison of conventional guaiac to four immunochemical methods for fecal occult blood testing: implications for clinical practice in hospital and outpatient settings. Clin Chim Acta 400 (2009), 120–122.
84. 84 Levy, B.T., Bay, C., Xu, Y., et al. Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy. J Med Screen 21 (2014), 133–143.
85. 85 Tao, S., Seiler, C.M., Ronellenfitsch, U., et al. Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer. Acta Oncol 52 (2013), 1667–1675.
86. 86 Auge, J.M., Pellise, M., Escudero, J.M., et al. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program. Gastroenterology 147 (2014), 628–636.e1.
87. 87 Wilschut, J.A., Hol, L., Dekker, E., et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 141 (2011), 1648–1655.e1.
88. 88 Cha, J.M., Lee, J.I., Joo, K.R., et al. Use of a low cut-off value for the fecal immunochemical test enables better detection of proximal neoplasia. Dig Dis Sci 58 (2013), 3256–3262.
89. 89 Levin, B., Lieberman, D.A., McFarland, B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134 (2008), 1570–1595.
90. 90 Plumb, A.A., Halligan, S., Pendse, D.A., et al. Sensitivity and specificity of CT colonography for the detection of colonic neoplasia after positive faecal occult blood testing: systematic review and meta-analysis. Eur Radiol 24 (2014), 1049–1058.
91. 91 Holleran, G., Leen, R., O'Morain, C., et al. Colon capsule endoscopy as possible filter test for colonoscopy selection in a screening population with positive fecal immunology. Endoscopy 46 (2014), 473–478.
92. 92 Nakama, H., Zhang, B., Immunochemical fecal occult blood test is inadequate for screening test of stomach cancer. Dig Dis Sci 45 (2000), 2195–2198.
93. 93 Liu, J., Finkelstein, S., Francois, F., Annual fecal occult blood testing can be safely suspended for up to 5 years after a negative colonoscopy in asymptomatic average-risk patients. Am J Gastroenterol 110 (2015), 1355–1358.
94. 94 Lieberman, D., Nadel, M., Smith, R.A., et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc 65 (2007), 757–766.
95. 95 Nadel, M.R., Berkowitz, Z., Klabunde, C.N., et al. Fecal occult blood testing beliefs and practices of U.S. primary care physicians: serious deviations from evidence-based recommendations. J Gen Intern Med 25 (2010), 833–839.
96. 96 Winawer, S.J., Zauber, A.G., Fletcher, R.H., et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 130 (2006), 1872–1885.
97. 97 Bampton, P.A., Sandford, J.J., Cole, S.R., et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut 54 (2005), 803–806.
98. 98 Lane, J.M., Chow, E., Young, G.P., et al. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia. Gastroenterology 139 (2010), 1918–1926.
99. 99 Sawhney, M.S., McDougall, H., Nelson, D.B., et al. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 55 (2010), 1637–1642.
100. 100 Levi, Z., Rozen, P., Hazazi, R., et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 104 (2009), 933–938.
101. 101 Brenner, H., Tao, S., Haug, U., Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 304 (2010), 2513–2520.
102. 102 Mandelli, G., Radaelli, F., Paggi, S., et al. Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study. Eur J Gastroenterol Hepatol 23 (2011), 323–326.
103. 103 Bujanda, L., Lanas, A., Quintero, E., et al. Effect of aspirin and antiplatelet drugs on the outcome of the fecal immunochemical test. Mayo Clin Proc 88 (2013), 683–689.
104. 104 Bujanda, L., Sarasqueta, C., Lanas, A., et al. Effect of oral anticoagulants on the outcome of faecal immunochemical test. Br J Cancer 110 (2014), 1334–1337.
105. 105 Collins, J.F., Lieberman, D.A., Durbin, T.E., et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 142 (2005), 81–85.
106. 106 Nakama, H., Zhang, B., Abdul Fattah, A.S., et al. Does stool collection method affect outcomes in immunochemical fecal occult blood testing?. Dis Colon Rectum 44 (2001), 871–875.
107. 107 Grazzini, G., Ventura, L., Zappa, M., et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 59 (2010), 1511–1515.
108. 108 van Roon, A.H., Hol, L., van Vuuren, A.J., et al. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol 107 (2012), 99–107.
109. 109 Cha, J.M., Lee, J.I., Joo, K.R., et al. Performance of the fecal immunochemical test is not decreased by high ambient temperature in the rapid return system. Dig Dis Sci 57 (2012), 2178–2183.
110. 110 Chausserie, S., Levillain, R., Puvinel, J., et al. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening. Int J Cancer 136 (2015), 1827–1834.
111. 111 van Rossum, L.G., van Rijn, A.F., van Oijen, M.G., et al. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer 125 (2009), 746–750.
112. 112 Dancourt, V., Hamza, S., Manfredi, S., et al. Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colorectal cancer screening. Eur J Cancer Prev 25 (2016), 109–114.
113. 113 Rex, D.K., Schoenfeld, P.S., Cohen, J., et al. Quality indicators for colonoscopy. Am J Gastroenterol 110 (2015), 72–90.
114. 114 Chiu, S.Y., Chuang, S.L., Chen, S.L., et al. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program. Gut, 2015 http://dx.doi.org/10.1016/j.gie.2016.09.025 [Epub ahead of print].
115. 115 National Cancer Screening Service. Guidelines for quality assurance in colorectal cancer screening. 1st ed. Dublin, 2012 Available from: http://www.cancerscreening.ie/publications/Guidelines-for-Quality-Assurance-in-Colorectal-Screening.pdf. Accessed: November 16, 2014.
116. 116 Green, B.B., Wang, C.Y., Anderson, M.L., et al. An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. Ann Intern Med 158 (2013), 301–311.
117. 117 Rabeneck, L., Tinmouth, J.M., Paszat, L.F., et al. Ontario's ColonCancerCheck: results from Canada's first province-wide colorectal cancer screening program. Cancer Epidemiol Biomarkers Prev 23 (2014), 508–515.
118. 118 Logan, R.F., Patnick, J., Nickerson, C., et al. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 61 (2012), 1439–1446.
119. 119 Malila, N., Oivanen, T., Malminiemi, O., et al. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ, 337, 2008, a2261.
120. 120 Chubak, J., Garcia, M.P., Burnett-Hartman, A.N., et al. Time to colonoscopy after positive fecal blood test in four U.S. health care systems. Cancer Epidemiol Biomarkers Prev 25 (2016), 344–350.